查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963806

惡性間皮癌治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年

Malignant Mesothelioma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球惡性間皮癌治療市場預計將從 2025 年的 2.6062 億美元成長到 2031 年的 3.8221 億美元，複合年成長率為 6.59%。

該市場涵蓋了針對心臟、腹部以及肺部胸膜、腹膜和肺膜惡性腫瘤的特異性藥物治療方法，例如化療、免疫療法和標靶治療。市場成長的主要促進因素是監管機構核准的雙重免疫療法通訊協定的日益普及，以及在有工業暴露史的地區石棉相關病例的持續高發，這代表的是結構性需求，而非暫時的處方趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 2.6062億美元
市場規模：2031年 3.8221億美元
複合年成長率：2026-2031年 6.59%
成長最快的細分市場 口服
最大的市場 北美洲

由於間皮瘤極為罕見，難以收回巨額研發成本，這是市場成長的一大障礙。根據美國癌症協會預測，2025年，美國每年新增間皮瘤病例約3,000例。如此有限的患者群體限制了新治療方法的商業性潛力，使得後期臨床試驗難以招募到足夠的受試者，從而減緩了治療方法進展的步伐。

市場促進因素

化療的快速發展和創新聯合治療的核准，正在從根本上重塑全球惡性間皮癌治療市場。製藥公司正成功地開發出超越傳統化療單藥療法的治療方法，例如引入免疫查核點抑制劑，從而提高無法手術切除患者的存活率。美國食品藥物管理局(FDA) 於 2024 年 9 月發布的新聞稿核准了Pembrolizumab聯合治療用於化療進行性或轉移性惡性肋膜間質細胞瘤，便是這一轉變的典型例證。該決定基於療效數據，數據顯示與單獨化療相比，聯合療法可降低 21% 的死亡風險，這不僅揭示了一種新的治療機制，也推動了昂貴生物製藥的應用。

由於間皮瘤潛伏期長，且患者長期接觸石棉，因此市場對該疾病的需求持續旺盛，儘管石棉目前已被禁用，已開發國家的患者數量仍然穩定。這種持續的發病率確保了需要治療的患者群體的穩定性，英國健康與安全署 (HSE) 2024 年 8 月發布的報告《英國間皮瘤統計數據 (2024)》證實了這一點（2022 年英國有 2257 人死於間皮瘤）。這種持續的高發生率也為專業公司帶來了可觀的收入。正如 Novocure 公司 2024 年財務報告所示，該公司第三季收入淨額達到 1.551 億美元，這主要得益於其專有療法在關鍵市場的推出。

市場挑戰

惡性間皮癌患者數量稀少，這構成了一項重大的經濟障礙，直接限制了全球治療領域的擴張。儘管製藥公司投入巨額研發資金開發特效治療方法，但全球患者數量的有限性使得這些巨額投資的商業性回報管道十分狹窄。高額資本投入與低潛在銷售量之間的這種不平衡，阻礙了企業優先開發間皮瘤計劃，導致新藥研發管線萎縮，參與企業也遠少於其他常見腫瘤領域。

此外，極少的患者數量為進行必要的臨床試驗帶來了巨大的後勤挑戰。大規模研究難以招募到足夠數量的合格受試者，這往往會導致入組時間延長和監管申報延遲。例如，澳洲健康與人類服務研究所報告稱，2024年該國僅新增684例間皮瘤病例，這表明主要市場低發病率如何分散了可用的試驗人群，延長了研發週期，並延緩了創新治療方法的上市。

市場趨勢

針對Hippo路徑的小分子抑制劑的研發正逐漸成為一種精準的治療策略，尤其適用於由NF2突變引起的間皮瘤。這些新型藥物旨在抑制YAP/TAZ和TEAD蛋白之間的相互作用，從而有效阻斷驅動癌細胞增殖的轉錄活性。根據2025年10月發表於Fierce Biotech的一項中期臨床試驗報告，實驗性TEAD抑制劑VT3989在難治性患者中實現了40週的中位無惡化生存期，顯著優於標準挽救化療15週的基準值。這為全身性治療提供了一個重要的替代方案。

同時，標靶治療的興起正在改變這一領域，使人們重新關注以這種表面蛋白為目標的免疫誘導細胞療法。研發人員正在增加嵌合體抗原受體（CAR）T細胞療法與查核點抑制劑的聯合應用，以應對胸膜惡性腫瘤特有的免疫抑制性腫瘤微環境。最近一項研究採用靶向絲氨酸的CAR T細胞療法聯合Pembrolizumab，實現了23.9個月的中位總生存期，這表明這種多管齊下的治療方法有望超越傳統的二線治療方案。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：惡性間皮癌治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（Pemetrexed、Cisplatin、Carboplatin、Gemcitabine、Vinorelbine、其他）
    • 給藥途徑（口服、注射）
    • 依最終用戶（醫院、癌症中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美惡性間皮癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲惡性間皮癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區惡性間皮癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲惡性間皮癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲惡性間皮癌治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球惡性間皮癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi SA
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18836

The Global Malignant Mesothelioma Therapeutics Market is projected to expand from USD 260.62 Million in 2025 to USD 382.21 Million by 2031, registering a compound annual growth rate of 6.59%. This market encompasses specialized pharmacological treatments, such as chemotherapy, immunotherapy, and targeted agents, designed to combat aggressive malignancies arising in the mesothelial linings of the heart, abdomen, or lungs. Market growth is primarily driven by the increasing implementation of regulatory-approved dual immunotherapy protocols and the enduring prevalence of asbestos-related cases in areas with a history of industrial exposure, representing structural demand rather than temporary prescription trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 260.62 Million
Market Size 2031USD 382.21 Million
CAGR 2026-20316.59%
Fastest Growing SegmentOral
Largest MarketNorth America

A significant obstacle hindering market growth is the difficulty in recouping substantial research and development expenditures given the condition's extreme rarity. The American Cancer Society reports that in 2025, the United States will see approximately 3,000 new mesothelioma diagnoses annually. This small patient base constrains the commercial potential of new treatments and makes recruiting adequate numbers of participants for late-stage clinical trials challenging, ultimately retarding the speed of therapeutic advancement.

Market Driver

The Global Malignant Mesothelioma Therapeutics Market is being fundamentally reshaped by rapid progress in immunotherapy and the authorization of innovative drug combinations. Pharmaceutical companies are successfully advancing beyond conventional chemotherapy-only regimens by deploying immune checkpoint inhibitors that offer improved survival outcomes for unresectable disease. This transition is highlighted by the U.S. Food and Drug Administration's September 2024 press release regarding the approval of pembrolizumab combined with chemotherapy for advanced or metastatic malignant pleural mesothelioma; this decision was supported by efficacy data indicating a 21% reduction in the risk of death compared to chemotherapy alone, a milestone that validates new mechanisms and compels the adoption of premium biologics.

Continued market demand is anchored by the long latency period of the disease and the legacy of extensive asbestos exposure, which maintains stable patient numbers in industrialized nations despite current bans. This persistent incidence ensures a steady population requiring treatment, as evidenced by the Health and Safety Executive's 'Mesothelioma Statistics for Great Britain, 2024' report from August 2024, which recorded 2,257 mesothelioma deaths in 2022. Such consistent prevalence sustains revenue for specialized companies, as reflected in Novocure's 2024 financial report showing third-quarter net revenues of $155.1 million, largely attributed to the uptake of its proprietary therapy in key markets.

Market Challenge

The scarcity of malignant mesothelioma presents a major economic obstacle that directly constrains the expansion of the global therapeutics sector. Manufacturers incur immense research and development expenses to create specialized therapies, yet the restricted global patient population provides a limited commercial path for recouping these heavy investments. This imbalance between high capital requirements and low potential sales volumes disincentivizes companies from prioritizing mesothelioma projects, resulting in a diminished pipeline of new drug candidates and fewer market participants compared to more common cancer indications.

Additionally, the rarity of patients imposes significant logistical challenges on the conduct of essential clinical trials. Obtaining a sufficient number of eligible subjects for large-scale studies is arduous, frequently causing prolonged enrollment phases and delays in regulatory filings. For instance, the Australian Institute of Health and Welfare noted in 2024 that only 684 new mesothelioma cases were diagnosed in Australia, illustrating how low incidence rates in major markets fragment the available trial population, thereby extending development timelines and retarding the entry of innovative therapies into the market.

Market Trends

The development of small molecule inhibitors targeting the Hippo pathway is emerging as a precise therapeutic strategy, particularly for mesothelioma driven by NF2 mutations. These novel agents are engineered to obstruct the interaction between YAP/TAZ and TEAD proteins, effectively halting the transcriptional activity that powers cancer cell growth. According to an October 2025 article by Fierce Biotech regarding a midstage trial, the experimental TEAD inhibitor VT3989 achieved a median progression-free survival of 40 weeks in treatment-resistant patients, significantly surpassing the 15-week benchmark of standard salvage chemotherapy and offering a vital alternative to systemic treatments.

Concurrently, the rise of mesothelin-targeted therapies is transforming the field, with a renewed emphasis on cellular interventions directing the immune system toward this surface protein. Developers are increasingly combining chimeric antigen receptor (CAR) T-cell therapies with checkpoint inhibitors to tackle the immunosuppressive tumor microenvironment typical of pleural malignancies. A report from Mesothelioma.com in August 2025 highlighted a recent study where mesothelin-targeted CAR T-cell therapy combined with pembrolizumab resulted in a median overall survival of 23.9 months, underscoring the potential of this multimodal approach to exceed historical second-line treatment outcomes.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi S.A.
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

Report Scope

In this report, the Global Malignant Mesothelioma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malignant Mesothelioma Therapeutics Market, By Drug Type

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Malignant Mesothelioma Therapeutics Market, By Route of Administration

  • Oral
  • Parenteral

Malignant Mesothelioma Therapeutics Market, By End User

  • Hospitals
  • Cancer Centers
  • Others

Malignant Mesothelioma Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malignant Mesothelioma Therapeutics Market.

Available Customizations:

Global Malignant Mesothelioma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malignant Mesothelioma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others)
    • 5.2.2. By Route of Administration (Oral, Parenteral)
    • 5.2.3. By End User (Hospitals, Cancer Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Malignant Mesothelioma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malignant Mesothelioma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Malignant Mesothelioma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Malignant Mesothelioma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By End User

7. Europe Malignant Mesothelioma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By End User
    • 7.3.2. France Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Malignant Mesothelioma Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By End User

8. Asia Pacific Malignant Mesothelioma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End User
    • 8.3.2. India Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Malignant Mesothelioma Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By End User

9. Middle East & Africa Malignant Mesothelioma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Malignant Mesothelioma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Malignant Mesothelioma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Malignant Mesothelioma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End User

10. South America Malignant Mesothelioma Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malignant Mesothelioma Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Malignant Mesothelioma Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Malignant Mesothelioma Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Malignant Mesothelioma Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck & Co. Inc.
  • 15.4. Pfizer Inc.
  • 15.5. Eli Lilly and Co.
  • 15.6. Sanofi S.A.
  • 15.7. AstraZeneca Plc
  • 15.8. Bayer AG
  • 15.9. Regeneron Pharmaceuticals Inc.
  • 15.10. GSK Plc

16. Strategic Recommendations

17. About Us & Disclaimer